

Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 20, 2012

September 13, 2012 1:12 PM ET

N. Billerica, Mass., September 13, 2012 – [Lantheus Medical Imaging, Inc.](http://www.lantheus.com), a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that Don Kiepert, President and Chief Executive Officer, will present at the Imperial Capital Global Opportunities Conference in New York City. The presentation will take place on Thursday, September 20, 2012, at 9:00 a.m., Eastern Time. Mr. Kiepert will provide an overview of the Company, the status of its products and a clinical development pipeline update.

To access a live webcast of the presentation, please visit the Company's website at www.lantheus.com. A replay of the presentation will be available on the Company's website for 30 days following the live presentation.

About Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company's proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border; ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease; TechnoLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com